LANCET:牛皮癣患者福音!新药Taltz赶走可怕的牛皮癣并发症

2017-05-30 Heather_z727 来宝网

由于自身免疫系统发生问题,牛皮癣可能带来其他严重的并发症,其中就包括银屑病关节炎。最新研究表明,一种新药物有助于缓解与牛皮癣有关的关节炎疼痛。


【新药Taltz治疗牛皮癣引起的关节炎效果显着】由于自身免疫系统发生问题,牛皮癣可能带来其他严重的并发症,其中就包括银屑病关节炎。最新研究表明,一种新药物有助于缓解与牛皮癣有关的关节炎疼痛。

根据斯坦福大学的研究人员带来的数据,银屑病会导致一种炎性关节疾病,这与失控的免疫反应有关。受到这种疾病影响的人数并不在少数。

银屑病关节炎通常发生在30岁之后,症状通常为关节僵硬,疼痛和肿胀,如果治疗结果不好,严重者会导致残疾。这项新研究的参与者是来自10个国家,超过300名的成年患者。这些患者会常规的药物已经没有反应。

在此次试验中,研究人员随机将参与者分为两组,分别使用新药Taltz,以及安慰剂进行治疗。治疗时长为6个月,其中一组每两周注射一次Taltz,另一组则接受安慰剂治疗。六个月之后,研究人员发现,使用Taltz进行治疗的一组中,关节肿胀程度得到大幅缓解的人数超过一半以上。

完整的研究报告发表于近期的《柳叶刀》杂志上。在此次报告中,研究人员表示:“银屑病关节炎是一种非常令人痛苦的疾病,此次研究是一个非常鼓舞人心的结果。全新药物的出现不仅为银屑病关节炎患者提供了全新的选择,也为治疗遇到瓶颈的患者带来了一丝新的希望。”

原始出处

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1828973, encodeId=874c18289e3f9, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 11 14:53:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674289, encodeId=18a816e4289e2, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17119, encryptionId=a5261e119fc, topicName=Taltz)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9a26964526, createdName=hjwang88, createdTime=Sun Dec 10 05:53:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757790, encodeId=0d391e577901e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Jan 13 02:53:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861095, encodeId=d69218610958f, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Oct 30 15:53:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321062, encodeId=e58b1321062d2, content=<a href='/topic/show?id=2a136e77095' target=_blank style='color:#2F92EE;'>#牛皮癣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67770, encryptionId=2a136e77095, topicName=牛皮癣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Thu Jun 01 04:53:00 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
    2017-10-11 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1828973, encodeId=874c18289e3f9, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 11 14:53:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674289, encodeId=18a816e4289e2, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17119, encryptionId=a5261e119fc, topicName=Taltz)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9a26964526, createdName=hjwang88, createdTime=Sun Dec 10 05:53:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757790, encodeId=0d391e577901e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Jan 13 02:53:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861095, encodeId=d69218610958f, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Oct 30 15:53:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321062, encodeId=e58b1321062d2, content=<a href='/topic/show?id=2a136e77095' target=_blank style='color:#2F92EE;'>#牛皮癣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67770, encryptionId=2a136e77095, topicName=牛皮癣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Thu Jun 01 04:53:00 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
    2017-12-10 hjwang88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1828973, encodeId=874c18289e3f9, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 11 14:53:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674289, encodeId=18a816e4289e2, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17119, encryptionId=a5261e119fc, topicName=Taltz)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9a26964526, createdName=hjwang88, createdTime=Sun Dec 10 05:53:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757790, encodeId=0d391e577901e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Jan 13 02:53:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861095, encodeId=d69218610958f, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Oct 30 15:53:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321062, encodeId=e58b1321062d2, content=<a href='/topic/show?id=2a136e77095' target=_blank style='color:#2F92EE;'>#牛皮癣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67770, encryptionId=2a136e77095, topicName=牛皮癣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Thu Jun 01 04:53:00 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
    2018-01-13 丁鹏鹏
  4. [GetPortalCommentsPageByObjectIdResponse(id=1828973, encodeId=874c18289e3f9, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 11 14:53:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674289, encodeId=18a816e4289e2, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17119, encryptionId=a5261e119fc, topicName=Taltz)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9a26964526, createdName=hjwang88, createdTime=Sun Dec 10 05:53:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757790, encodeId=0d391e577901e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Jan 13 02:53:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861095, encodeId=d69218610958f, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Oct 30 15:53:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321062, encodeId=e58b1321062d2, content=<a href='/topic/show?id=2a136e77095' target=_blank style='color:#2F92EE;'>#牛皮癣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67770, encryptionId=2a136e77095, topicName=牛皮癣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Thu Jun 01 04:53:00 CST 2017, time=2017-06-01, status=1, ipAttribution=)]
    2017-10-30 shizhenshan
  5. [GetPortalCommentsPageByObjectIdResponse(id=1828973, encodeId=874c18289e3f9, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Oct 11 14:53:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674289, encodeId=18a816e4289e2, content=<a href='/topic/show?id=a5261e119fc' target=_blank style='color:#2F92EE;'>#Taltz#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17119, encryptionId=a5261e119fc, topicName=Taltz)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a9a26964526, createdName=hjwang88, createdTime=Sun Dec 10 05:53:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757790, encodeId=0d391e577901e, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Sat Jan 13 02:53:00 CST 2018, time=2018-01-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861095, encodeId=d69218610958f, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Oct 30 15:53:00 CST 2017, time=2017-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321062, encodeId=e58b1321062d2, content=<a href='/topic/show?id=2a136e77095' target=_blank style='color:#2F92EE;'>#牛皮癣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67770, encryptionId=2a136e77095, topicName=牛皮癣)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c2e485, createdName=yangfl06, createdTime=Thu Jun 01 04:53:00 CST 2017, time=2017-06-01, status=1, ipAttribution=)]

相关资讯

JAMA Dermatol:牛皮癣可能与糖尿病和肥胖发生相关

一项新的研究表明,慢性皮肤癣病可能与超重和2型糖尿病发病相关。丹麦的研究人员发现,与正常者相比,患有2型糖尿病者有牛皮癣的概率超过50%。研究还发现,牛皮癣发生率与体重上升有关。例如,身高体重指数(BMI)超过35的肥胖者患牛皮癣的概率比一般体重正常者高2倍。虽然这些条件是如何联系起来的尚不明确,但是研究人员相信,这与遗传、吸烟、酒精、炎症等因素有关。哥本哈根大学研究者Ann Sophie Lon

NEJM:新药物ixekizumab可根治牛皮癣

  牛皮癣(也叫银屑病)是一种因皮肤细胞变异而导致皮肤红肿的疾病,不同的患者牛皮癣的严重程度并不相同。一直以来,这种疾病没有治愈的方法。不过,最近美国科学家们开发出一种新的药物可能能够改变这一现状。 经过长期的临床试验,70%-80%的牛皮癣患者能够完全治愈,这是十分令人惊喜的结果。 该药物叫做“ixekizumab”,将能够解决世界上3%人群的心头之患。 牛皮癣患者需要面

PNAS:得了牛皮癣,不再得脚气?

真菌感染是目前人类微生物致病的主要来源之一。在免疫缺陷的患者中,微不足道的真菌感染往往却是致命的。人类的肺器官每天清理无数的空气中的真菌孢子,同时却不引起炎症反应,说明表皮组织也具有抗真菌的能力,其中为大家所熟知的是表皮细胞分泌的抗菌肽。另外一个奇怪的现象是在患有一些皮肤病的患者中(例如牛皮癣),患病的部位对于真菌感染也具有极强的抵抗力。因此,可能牛皮癣病变部位含有可以抵抗真菌感染的成分。对此

Nat Commun:科学家找到牛皮癣新靶点,根除牛皮癣不再是个“梦”

从表面上看,牛皮癣和过敏性皮炎看起来好像差别不大,但实际则不然。过敏性皮炎,也称为湿疹,主要是一种过敏反应。而牛皮癣则是一种自身免疫性疾病。

Ciculation:如何降低牛皮癣患者冠状动脉疾病的发病率?

牛皮癣是与加速MI风险相关的慢性炎性疾病,提供了一种理想的人体模型来研究炎症性动脉粥样硬化。研究人员假设:如果在牛皮癣患者中观察到了增加的心血管风险,将部分归因于由具有高风险特征的非钙化斑块组成的升高的亚临床冠状动脉疾病(CAD)。然而,在这个弱势群体中,没有足够试验直接衡量CAD。